Home > Healthcare > Medical Devices > Medical Supplies > Safety Syringes Market
Safety Syringes Market Size, Analysis, Regional Outlook, Application Development Potential, Price Trends, Competitive Market Share & Forecast, 2024 – 2032
- Report ID: GMI3336
Safety Syringes Market Size
Safety Syringes Market is expected to record significant growth during the forecast period 2024-2032, owing to the growing prevalence chronic disorders worldwide. Rising cases of needlestick injuries amongst healthcare professionals are increasing the product demand. In February 2022, needlestick injuries pose a significant occupational health hazard globally, affecting around 3 million healthcare workers.
Additionally, there is an introduction of government initiatives to integrate the use of safety syringes and favorable reimbursement policies. In January 2023, MTD Group attained FDA clearance for DropSafe Sicura, a passive safety needle for the intramuscular and subcutaneous injection of vaccines and other drugs, featuring a fully passive mechanism.
Safety Syringes Market Trends
There is an increasing integration of retractable needle systems, offering enhanced protection against needlestick injuries for healthcare professionals. Moreover, the market is witnessing a shift toward the product adoption with passive safety mechanisms, reducing the need for user activation and ensuring foolproof safety during injections. The heightened awareness of infectious diseases and a proactive approach to infection prevention are further propelling the industry progression.
Safety Syringes Market Analysis
Based on the product, retractable syringes segment will hold a substantial share by 2032, as they help in reducing the risk of needlestick injuries. The design of these syringes not only minimizes the risk of accidental needlestick injuries but also enhances overall user safety and patient care. As per WHO, approximately 58 million people had chronic hepatitis C virus infection, and around 1.5 million new infections occurred each year. The increasing awareness of the potential transmission of bloodborne infections such as Hepatitis C, Hepatitis B, and others has fueled the demand for retractable syringes.
As per end-user, ambulatory surgical centers segment is expected to record significant gains during 2024-2032, as there is a heightened focus on implementing stringent safety measures to protect both healthcare professionals and patients. The increased adoption of safety syringes in these centers is driven by a commitment to providing a secure and hygienic environment for medical procedures.
North America safety syringes market size will expand significantly in the forthcoming years, driven by the constant immunization programs, growing prevalence of chronic disorders, and increasing employment of safety syringes over conventional syringes. As per AHA.org., an estimated 133 million Americans—around half the population—suffer from at least one chronic illness, such as hypertension, cardiac disease, and arthritis. With the vaccination drives for various diseases & infections in U.S. and Canada, the central governments are producing new regulations and deals to shorten the supply and demand gap for vaccines.
Safety Syringes Market Share
Some of the major safety syringe industry players include:
- JMI Syringes & Medical Device
- Medtronic
- Smiths Medical Inc.
- Becton Dickinson
- B.Braun (B. Braun Holding GmbH & Co. KG)
- Boston Scientific Corporation
- Retractable Technologies Inc.
These conglomerates are engaged in various marketing strategies like mergers and acquisitions, product launches, and partnerships to secure a prominent position place in the overall marketplace.
Safety Syringes Industry News
- In February 2022, JMI Syringes and Medical Devices Ltd received a purchase order to export 4.5 crore auto-disable (AD) syringes made in Bangladesh to Dubai for the Covid-19 vaccination program.
- In October 2023, B. Braun Medical Inc., a frontrunner in intelligent infusion therapy, unveiled Introcan Safety® 2 IV Catheter featuring Multi-Access Blood Control. The product is a result of the company’s commitment to passive needlestick prevention and marks a significant advancement in its series of catheter innovations.
What Information does this report contain?
